Organogenesis Holdings Inc. financial data

Symbol
ORGO on Nasdaq
Industry
Pharmaceutical Preparations
Location
85 Dan Road, Canton, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
Avista Healthcare Public Acquisition Corp. (to 12/10/2018)
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 283 % -1.59%
Quick Ratio 33.7 % -0.53%
Debt-to-equity 64.6 % -4.84%
Return On Equity -2.69 % -156%
Return On Assets -1.63 % -157%
Operating Margin -2.81 % -156%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 133M shares +0.41%
Common Stock, Shares, Outstanding 133M shares +0.96%
Entity Public Float 236M USD -31.7%
Common Stock, Value, Issued 13K USD 0%
Weighted Average Number of Shares Outstanding, Basic 133M shares +0.96%
Weighted Average Number of Shares Outstanding, Diluted 134M shares +0.38%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 455M USD +1.34%
Cost of Revenue 112M USD +6.27%
Research and Development Expense 50.5M USD +14.8%
Operating Income (Loss) -12.8M USD -157%
Nonoperating Income (Expense) -2.09M USD -33%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -14.9M USD -171%
Income Tax Expense (Benefit) -7.48M USD -194%
Net Income (Loss) Attributable to Parent -7.38M USD -157%
Earnings Per Share, Basic -0.06 USD/shares -160%
Earnings Per Share, Diluted -0.06 USD/shares -160%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 94.3M USD -3.96%
Accounts Receivable, after Allowance for Credit Loss, Current 101M USD +13.4%
Inventory, Net 27M USD -3.11%
Assets, Current 239M USD +5.74%
Deferred Income Tax Assets, Net 35.9M USD +19.6%
Property, Plant and Equipment, Net 89.9M USD -23.5%
Operating Lease, Right-of-Use Asset 34.9M USD -17.5%
Intangible Assets, Net (Excluding Goodwill) 13.3M USD -22.2%
Goodwill 28.8M USD 0%
Other Assets, Noncurrent 5.01M USD +279%
Assets 446M USD -3.53%
Accounts Payable, Current 24M USD -10.5%
Employee-related Liabilities, Current 22.8M USD +1.81%
Accrued Liabilities, Current 36.1M USD +3.17%
Liabilities, Current 77.3M USD -5.16%
Operating Lease, Liability, Noncurrent 22.8M USD -41.3%
Other Liabilities, Noncurrent 1.29M USD +8.65%
Liabilities 168M USD -9.71%
Retained Earnings (Accumulated Deficit) -47.8M USD -18.3%
Stockholders' Equity Attributable to Parent 279M USD +0.61%
Liabilities and Equity 446M USD -3.53%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -10.2M USD -100%
Net Cash Provided by (Used in) Financing Activities -2.61M USD -111%
Net Cash Provided by (Used in) Investing Activities -2.22M USD +70.6%
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 133M shares +0.96%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -15M USD -8.05%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 94.9M USD -3.95%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1.38M USD +8.18%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 41.3M USD -4.91%
Operating Lease, Liability 45.5M USD -14.3%
Depreciation 10.8M USD +50.5%
Payments to Acquire Property, Plant, and Equipment 2.22M USD -70.6%
Lessee, Operating Lease, Liability, to be Paid 52.5M USD -15.6%
Property, Plant and Equipment, Gross 144M USD +12.5%
Operating Lease, Liability, Current 3.93M USD -69.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 6.99M USD -23%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1M shares 0%
Unrecognized Tax Benefits 1.62M USD -0.8%
Operating Lease, Payments 2.72M USD +10%
Amortization of Intangible Assets 3.8M USD -22.6%
Depreciation, Depletion and Amortization 3.57M USD +40.3%
Deferred Tax Assets, Net of Valuation Allowance 28M USD -6.7%
Interest Expense 2.08M USD +16.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%